ESTRO 2024 - Abstract Book

S445

Clinical - Biomarkers

ESTRO 2024

This study combines high-dimensional molecular information with radiomic signatures to improve our understanding of biological underpinnings of clinically relevant radiomic data. We were able to show that molecular signatures of immune cell composition extracted from melanoma metastases are predictive of progression and overall survival in patients treated with immune checkpoint inhibitors. More importantly, we showed that characteristics of these molecular signatures can be non-invasively captured by routine PET/CT imaging and quantitatively described by radiomic features.

* These authors contributed equally to this work

Keywords: radiomics, melanoma, immunotherapy

References:

1. Gabryś HS, Basler L, Burgermeister S, et al. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. Front Oncol. 2022;12. Accessed October 25, 2023. https://www.frontiersin.org/articles/10.3389/fonc.2022.977822 2. Sun R, Lerousseau M, Briend-Diop J, et al. Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. J Immunother Cancer. 2022;10(10):e004867. doi:10.1136/jitc-2022-004867

3. Irmisch A, Bonilla X, Chevrier S, et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell. 2021;39(3):288-293. doi:10.1016/j.ccell.2021.01.004